What to expect from imiquimod treatment for basal cell carcinoma

Basal cell carcinoma is a skin cancer that may appear as a shiny bump, a persistent sore, a scaly patch, or a spot that bleeds easily. Imiquimod is a topical immune-response medicine used for selected superficial cancers when the site and depth make this approach suitable. It is not appropriate for every basal cell carcinoma, particularly lesions with features that require another treatment or a deeper assessment.

The treated skin commonly becomes red, inflamed, scaly, crusted, or sore as the medicine acts. The appearance may be uncomfortable and can take time to settle after applications finish. A follow-up examination is essential because a surface reaction alone cannot confirm that all cancer cells have been cleared.

Apply only to the biopsy-confirmed area and according to the exact schedule supplied by your dermatologist. Wash hands before and after application, avoid the eyes and mucous membranes, and do not cover the site unless instructed. Keep the area protected from sunlight, avoid picking crusts, and use gentle cleansing while the skin heals.

Report other creams, immune conditions, pregnancy, and medicines before starting. If the reaction becomes severe, contact the dermatology team rather than silently reducing or extending the course. Keep the review appointment even if the lesion looks better.

Contact your dermatologist promptly for severe pain, spreading redness, heavy bleeding, pus-like drainage, deep ulceration, or a reaction that prevents normal activities. Seek urgent help for breathing difficulty, facial or throat swelling, or a widespread allergic reaction. Return for assessment if a lump, sore, bleeding point, or thickened area persists after healing.

Ask why your lesion is suitable for imiquimod, how its margins were identified, what reaction is expected, how healing will be supported, and when follow-up will determine whether more treatment is needed.